PDF下载 ( 170 KB)
Short-term clinical effect of telbivudine in the treatment chronic hepatitis B
-
摘要: 目的研究替比夫定(LdT)对慢性乙型肝炎治疗近期疗效和安全性。方法慢性乙型肝炎患者口服替比夫定。患者包括初次使用替比夫定患者21例和阿德福韦酯原发治疗失败后换用替比夫定患者16例两组。治疗前后测定基线HBVDNA水平、HBVM、肝肾功能、肌酸肌酶。结果两组患者治疗1月、3月、6月后ALT较治疗前明显下降(P<0.05),两组之间治疗前后ALT比较没有显著性差异(P>0.05)。两组患者治疗1月log值下降幅度无明显差异(P>0.05),治疗3月、6月后log值下降幅度差异有统计学意义(P<0.05)。初次用药与更换用药在HBVDNA转阴和HBeAg血清转换方面在治疗6月内差异无统计意义(P>0.05)。结论替比夫定治疗慢性乙型肝炎,可迅速减少肝损伤和降低HBVDNA病毒载量,3、6月时初次用药降低病毒载量优于阿德福韦酯原发治疗失败后更换用药者。Abstract: Objective To study the efficacy and safety of telbivudine in the treatment of chronic hepatitis B (CHB) .Methods A total 37 patients with CHB were divided in to two groups.Group one (n=21) patients were treated with telbivudine from the beginning and group two (n=16) patients were treated with telbivudine after treatment failure with adefovir dipivoxil.Each patient received 600mg daily for 24 weeks.Serum ALT, HBV DNA and creatine kinase levels were measured before and after treatment.Results After treatment, the level of serum ALT decreased dramatically in both groups (p<0.05) but the decrease was not statistically significant between the two groups.After one month of treatment the mean reduction of HBV DNA from baseline didn't show significant difference between the two groups, but it reduced significantly after 3 to 6 months of treatment (p<0.05) .There was no significant difference in HBV DNA level and HBeAg seroconversion between the two groups at the end of treatment.Conclusion Telbivudine seems to be effective and safe in viral load reduction if it is taken at the beginning of treatment.
-
Key words:
- telbivudine /
- hepatitis B
-
[1]庄辉.病毒性肝炎的流行病学[J].中国计划免疫, 2004, 10 (3) ∶180-181. [2]Hodge RA.Telbivudine/Torcitabine idenix/Novartis[J].Curr Op in Invest Drugs, 2004, 5∶232-241. [3]Tacke F, Trautwein C.Hepatitis B goes globe:Telbivudine as a new treatment option[J].Hepatology, 2008, 47 (5) ∶1786-1787. [4]汪月娥.耐药所致治疗失效的临床结局[J].肝脏, 2007, 12 (增刊) ∶37-39. [5] 中华医学会.慢性乙型肝炎防治指南[J].中华肝脏病杂志, 2005, 13∶881-891. [6]梁月兰, 黄春新.治疗慢性乙肝新药-素比伏 (替比夫定片) [J].中南药学, 2007, 5 (3) ∶285-287. [7]Zhou XJ, Lim SG, Lloyd DM, et al.Pharmacokinetics of telbivudine following oral administration of escalating single and multip le doses in patientswith chronic hepatitis B virus infection:pharrnacodynamic implications[J].Antimicrob Agents Chemother, 2006, 50 (3) ∶874-879.[8]许洁, 陆志檬.替比夫定治疗慢性乙型肝炎的进展[J].中华肝脏病杂志, 2006, 14 (12) ∶958-960. [9]Zhou XJ, Fielman BA, Lloyd DM, et al.Pharmacokinetics of telbivu-dine in healthy subjects and absence of drug interaction with lamivu-dine or adefovir dip ivoxil[J].Antimicrob Agents Chemother, 2006, 50 (7) ∶2309-2315. [10]邓中平.恩替卡韦治疗乙型肝炎的疗效及安全性[J].中国新药与临床杂志, 2005, 24 (4) ∶326-329. [11]张雪松, 金瑞.替比夫定单用及与阿德福韦或干扰素联用出现肌病的初步观察[J].药物不良反应杂志, 2008, 10 (3) ∶180-183. [12]Kohnke H, Sorl INK, Granath G, et al.Warfarin dose related to apo-lipop rotein E (APOE) genotype[J].Eur J Clin Pharm acol, 2005, 61 (5-6) ∶381-388. -
本文二维码
计量
- 文章访问数: 2329
- HTML全文浏览量: 14
- PDF下载量: 815
- 被引次数: 0
下载:
